A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the
safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain
metastases). ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle).
Each patient will participate in only 1 dose group and will receive up to 6 cycles of
treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1
or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute
neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.